Ascendis Pharma A/S (ASND) Upgraded to Buy at BidaskClub

BidaskClub upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a buy rating in a research report released on Wednesday.

Several other research firms also recently commented on ASND. Bank of America raised their price objective on Ascendis Pharma A/S from $36.00 to $46.00 in a report on Thursday, September 28th. Leerink Swann reaffirmed a hold rating and set a $28.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, September 1st. HC Wainwright reaffirmed a buy rating on shares of Ascendis Pharma A/S in a research report on Wednesday, December 13th. Credit Suisse Group reaffirmed an outperform rating and set a $50.00 target price (up previously from $30.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Finally, Wedbush reaffirmed an outperform rating and set a $10.71 target price (down previously from $65.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $36.45.

Ascendis Pharma A/S (NASDAQ ASND) opened at $40.09 on Wednesday. The company has a market capitalization of $1,460.00 and a price-to-earnings ratio of -10.25. Ascendis Pharma A/S has a fifty-two week low of $19.21 and a fifty-two week high of $42.00.

A number of hedge funds and other institutional investors have recently made changes to their positions in ASND. Bank of America Corp DE boosted its position in shares of Ascendis Pharma A/S by 23.6% in the 1st quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 1,020 shares in the last quarter. Bank of Montreal Can boosted its position in shares of Ascendis Pharma A/S by 127.4% in the 2nd quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 2,541 shares in the last quarter. Alps Advisors Inc. boosted its position in shares of Ascendis Pharma A/S by 9.1% in the 3rd quarter. Alps Advisors Inc. now owns 31,929 shares of the biotechnology company’s stock worth $1,157,000 after purchasing an additional 2,665 shares in the last quarter. California Public Employees Retirement System boosted its position in shares of Ascendis Pharma A/S by 26.8% in the 3rd quarter. California Public Employees Retirement System now owns 19,658 shares of the biotechnology company’s stock worth $713,000 after purchasing an additional 4,158 shares in the last quarter. Finally, Victory Capital Management Inc. acquired a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth $194,000. 78.93% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Ascendis Pharma A/S (ASND) Upgraded to Buy at BidaskClub” was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.com-unik.info/2017/12/28/ascendis-pharma-as-asnd-upgraded-to-buy-at-bidaskclub.html.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

What are top analysts saying about Ascendis Pharma A/S? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ascendis Pharma A/S and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit